PRISM project

PRISM: Precision Medicine and Neurosymtomatics

The PRISM consortium’s principal aim is to help accelerate the development of treatments for psychiatric and neurological conditions such as schizophrenia and Alzheimer’s dementia. Currently these disorders are classified by the symptoms observed by a doctor, most often a psychiatrist or neurologist. Unlike the diagnoses of other diseases, this classification does not involve any measurement of the biological problems causing the symptoms. This disconnect between diagnosis and biology may be one of the reasons why treatment development has faced such challenges.

The PRISM project, awarded by the Innovative Medicines Initiative, was awarded to allow P1vital and our project Partners to probe the biological brain systems of traditionally-diagnosed schizophrenic and dementia patients using a wide range of state of the art quantitative technologies. This data is then analysed to see if patients can be clustered and differentiated based on the underlying impaired brain biology, paving the way to potentially novel ways of classifying and treating these debilitating disorders.

The initial programme of PRISM research was conducted between 2016-2019, the results of which are now being published for evaluation by the wider scientific community.

The PRISM group was successful in securing funding for an additional programme of research, which will include a third patient cohort of Major Depressive Disorder patients. This will further expand our understanding of differences and overlap in the underlying neurobiology of different psychiatric and neurological disorders.

The PRISM project website can be found here.

Learn about PRISM on YouTube. The PRISM group has produced a series of YouTube videos to explain our work. Watch them here.

P1vital’s PRISM Publications.

The fourth PRISM General Assembly and eighth Steering Committee Meeting, 07 – 08 February 2019, Basel Switzerland

The project leading to this application has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115916. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. This website reflects only the author’s views neither IMI JU nor EFPIA nor the European Commission are liable for any use that may be made of the information contained therein.

The project leading to this application has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115916. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. This website reflects only the author’s views neither IMI JU nor EFPIA nor the European Commission are liable for any use that may be made of the information contained therein.